pancreatic cancer
Conditions
Interventions
Administration of synthetic secretin
Sponsors
Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient provided informed consent at over 20 years old 2. Patients suspected of pancreatic cancer by image examination, or patients with IPMN which is classified as "high risk stigmata" or "worrisome features" by international consensus guidelines.
Exclusion criteria
Exclusion criteria: 1) Patients with hypersensitivity to secretin or other ingredients (excipients: glycine hydrochloride, glycine, and polypeline). 2) Patients within 2 weeks after remission from acute pancreatitis or acute exacerbations of chronic pancreatitis. 3) A pregnant or lactating woman. 4) Patients who received other research drugs or investigational drugs within 3 months prior to the start
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To examine the improvement of pancreatic cancer diagnostic ability by pancreatic juice cytology after secretin administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To verify pancreatic cancer diagnosis by exosome or cfDNA in pancreatic juice using synthetic secretin 2) To verify the pancreatic cancer diagnosis by MRI image using synthetic secretin | — |
Countries
Japan
Contacts
Public ContactYuri Sakamoto
Faculty of Medicine, Tottori University Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine,
Outcome results
None listed